1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. South & Central America Therapeutic Vaccines Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. South & Central America Therapeutic Vaccines Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. South & Central America Therapeutic Vaccines Market Regional Analysis
6.2 South & Central America Therapeutic Vaccines Market Revenue 2021-2031 (US$ Thousand)
6.3 South & Central America Therapeutic Vaccines Market Forecast Analysis
7. South & Central America Therapeutic Vaccines Market Analysis – by Product
7.1 Cancer Vaccine
- 7.1.1 Overview
- 7.1.2 Cancer Vaccine: South & Central America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Infectious Disease Vaccine
- 7.2.1 Overview
- 7.2.2 Infectious Disease Vaccine: South & Central America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
7.3 Others
- 7.3.1 Overview
- 7.3.2 Others : South & Central America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
8. South & Central America Therapeutic Vaccines Market Analysis – by Technology
8.1 Allogenic Vaccine and Autologus Vaccine
- 8.1.1 Overview
- 8.1.2 Allogenic Vaccine and Autologus Vaccine: South & Central America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
9. South & Central America Therapeutic Vaccines Market Analysis – by End User
9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Hospitals: South & Central America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
9.2 Clinics
- 9.2.1 Overview
- 9.2.2 Clinics: South & Central America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others : South & Central America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
10. South & Central America Therapeutic Vaccines Market – South and Central America Analysis
10.1 Overview
10.2 South and Central America
- 10.2.1 South & Central America Therapeutic Vaccines Market Breakdown, by Key
Country, 2024 and 2031 (%)
- 10.2.1.1 South & Central America Therapeutic Vaccines Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 Brazil:
South & Central America Therapeutic Vaccines Market – Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.1.1.1 Brazil: South & Central America Therapeutic Vaccines Market Breakdown, by Product
- 10.2.1.1.2 Brazil: South & Central America Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.1.1.3 Brazil: South & Central America Therapeutic Vaccines Market Breakdown, by End User
- 10.2.1.2 Argentina:
South & Central America Therapeutic Vaccines Market – Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.1.2.1 Argentina: South & Central America Therapeutic Vaccines Market Breakdown, by Product
- 10.2.1.2.2 Argentina: South & Central America Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.1.2.3 Argentina: South & Central America Therapeutic Vaccines Market Breakdown, by End User
- 10.2.1.3 Rest of South and Central America:
South & Central America Therapeutic Vaccines Market – Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.1.3.1 Rest of South and Central America: South & Central America Therapeutic Vaccines Market Breakdown, by Product
- 10.2.1.3.2 Rest of South and Central America: South & Central America Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.1.3.3 Rest of South and Central America: South & Central America Therapeutic Vaccines Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Dendreon
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 BioNTech SE
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Serum Institute of India Pvt. Ltd
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Merck & Co Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Amgen Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 ISA Pharmaceuticals BV
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 INOVIO Pharmaceuticals Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Transgene SA
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 THERAVECTYS SA
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 CureVac SE
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations